DECIDER (Improved clinical decisions via integrating multiple data levels to overcome chemotherapy resistance in high-grade serous ovarian cancer) is a research project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965193 from February 1, 2021 to January 31, 2026.
Main goals of DECIDER
The mains goals of DEDICER are to develop diagnostic tools and treatments for high-grade serous ovarian cancer with the help of AI methods. The aim is to identify earlier those patients who do not respond well to the first-line treatments, and to find effective treatments to patients with a drug-resistant cancer.
We also study the legal issues that impede or slow down the use of new treatments in order to facilitate commercialization and availability of personalized therapies in an ethically and legally sustainable manner.
University of Helsinki, Finland (Sampsa Hautaniemi, Olli Carpén, Päivi Korpisaari)
The Systems Biology of Drug Resistance in Cancer group
Professor Olli Carpén’s research group
Professor Korpisaari Research Group, Faculty of Law
Hospital District of Southwest Finland (Johanna Hynninen)
HUS Helsinki University Hospital, Finland (Anni Virtanen)
Karolinska Institutet, Sweden (Jussi Taipale)
Danish Cancer Society, Denmark (Tuula Kallunki)
Heidelberg University Hospital, Germany (Julio Saez-Rodriguez)
Institut Pasteur, France (Benno Schwikowski)
University of Modena and Reggio Emilia, Italy (Elisa Ficarra)
Insitute for Research in Biomedicine, Spain (Fran Supek)
Barcelona Supercomputing Center, Spain (Salvador Capella)
Aiforia Technologies Oy, Finland (Kaisa Helminen)
VEIL.AI Ltd, Finland (Tuomo Pentikäinen)
2cureX A/S, Denmark (Ole Thastrup)
AB ANALITICA s.r.l, Italy (Diego Boscarino)
Project scientific coordinator
+358 50 448 63 20